Shuttle Pharmaceuticals (SHPH)

What Moves the Stock

1. 01Phase 2 clinical trial data readouts for Ropidoxuridine in glioblastoma - interim analysis results or final efficacy/safety data
2. 02FDA regulatory milestones - IND approvals for new indications, Fast Track or Orphan Drug designations
3. 03Capital raising announcements - equity offerings, warrant exercises, or dilutive financings that impact share count
4. 04Partnership or licensing deals with larger pharmaceutical companies for development/commercialization rights
5. 05Patent grants or intellectual property developments protecting radiation sensitizer technology platform
6. 06No current revenue - pre-commercial clinical-stage company
7. 07Future potential: licensing agreements or partnerships for Ropidoxuridine if clinical trials succeed
8. 08Future potential: product sales post-FDA approval (estimated 2028-2030 at earliest if trials succeed)

SHPH Chart

My Notes

• momentum/speculative - SHPH attracts high-risk biotech speculators seeking 10-100x returns from clinical trial success…
• Rising interest rates negatively impact SHPH through two mechanisms: (1) higher discount rates compress NPV of distant future cash flows…
• Watch on earnings: Monthly cash burn rate and remaining cash runway (quarters of funding available), Phase 2 trial enrollment completion percentage and timeline to data readout, Nasdaq minimum bid price compliance - stock trading under $1 risks delisting, forcing reverse split.